DataMeds AI, Inc.
corporate_fare Company Profile
DataMeds AI, Inc. (NASDAQ:MEDS) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 24 items for MEDS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for MEDS spans PRE 14C, 8-K, 10-Q, S-1/A.
Recent high-impact activity:
- DataMeds Wins Consent for Axe Compute Note Conversion With Full-Ratchet Reset
- DataMeds AI Launches $10.0M At-The-Market Program With Dawson James
- DataMeds AI Q3: $10.5M Net Income on Debt-Extinguishment Gain, Going Concern Persists
- DataMEDS AI Swings to $10.5M Q3 Profit on Debt Extinguishment; Revenue Up 50% Sequentially
- Q3 Revenue Jumps 50% Sequentially as DataMEDS Swings to $10.5M Operating Profit
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 371,417 shares in MEDS as of the October 30, 2026 settlement, a 22.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 55.9% of MEDS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for MEDS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-17.
ATM Prospectus Supplement Filed · No Shares Sold Yet
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →